Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Hims & Hers Health in the transaction. Hims & Hers Health, a multi-specialty telehealth platform, announced its acquisition...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian acted as counsel to Tarsus Pharmaceuticals in the offering, Hogan Lovells acted as regulatory counsel while Knobbe Martens Olson...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented China Natural Resources, Inc. in the transaction, and Sheppard Mullin Richter & Hampton represented FT Global Capital, Inc.,...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Natera, and Davis Polk & Wardwell advised the representatives of the several underwriters on the offering. Natera, Inc....
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer advised sales agents Goldman Sachs & Co. LLC and SVB Securities on the deal. Goldman Sachs & Co. LLC and SVB Securities acted as sales agents in...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer and Skadden advised Anaplan on the deal. Kirkland and Ellis and Cadwalader, Wickersham & Taft advised Thoma Bravo. Latham & Watkins represented the direct...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Backblaze on the deal. White & Case advised Oppenheimer & Co. Backblaze, a provider of cloud storage and...
You must be a Standard 1 Year member to access this content.
Blank Rome advised Novus Capital Corporation on the deal while Gunderson Dettmer represented Energy Vault. Novus Capital Corporation, a publicly traded special purpose acquisition company, or...
You must be a Standard 1 Year member to access this content.
Davis Polk advised the joint book-running managers in the offering. The $646.9 million secondary offering of 20,700,000 shares of common stock of Maravai LifeSciences Holdings, Inc....
You must be a Standard 1 Year member to access this content.
